Pharmacology · Year 2 · from Pharmacology

Case 1: Managing Chemotherapy-Induced Nausea and Neutropenic Fever

Patient Demographics

• Age: 52 years
• Sex: Female
• Occupation: High school principal (on medical leave)

Chief Complaint

"I have a fever and I just finished my first chemotherapy last week."

History of Present Illness

A 52-year-old woman with newly diagnosed Stage IIB breast cancer (ER+/PR+/HER2-) presents to the emergency department with fever. She received her first cycle of dose-dense AC chemotherapy (doxorubicin + cyclophosphamide) 10 days ago. Despite taking antiemetic medications, she experienced significant nausea and vomiting for the first 4 days and had difficulty eating. She developed progressive fatigue over the past few days and today noticed a temperature of 38.6C (101.5F) at home. She has no localizing symptoms: no cough, dysuria, diarrhea, or skin changes. She has an implanted port for chemotherapy access.

Chemotherapy Regimen

Dose-Dense AC (every 2 weeks x 4 cycles):

• Doxorubicin 60 mg/m2 IV
• Cyclophosphamide 600 mg/m2 IV
• Pegfilgrastim 6 mg SC day 2 (G-CSF support)

Antiemetic Regimen Prescribed:

• Ondansetron 8 mg PO BID x 3 days
• Dexamethasone 8 mg PO daily x 3 days
• Aprepitant 125 mg day 1, then 80 mg days 2-3
• Prochlorperazine 10 mg PO q6h PRN

Physical Examination

• Vital Signs: T 38.9C (102F), BP 100/62 mmHg, HR 108 bpm, RR 20/min
• General: Ill-appearing, fatigued
• HEENT: Oral mucosa with mild mucositis; no thrush
• Port site: No erythema, tenderness, or drainage
• Lungs: Clear to auscultation
• Abdomen: Soft, non-tender
• Skin: No rashes, cellulitis, or perianal abnormalities

Workup

Laboratory Studies:

Additional Studies:

• Blood cultures x 2 sets (peripheral and from port): Pending
• Urinalysis: Negative
• Chest X-ray: No infiltrates

Diagnosis

Febrile Neutropenia

Definition:

• Fever: Single temperature >= 38.3C (101F) OR >= 38.0C (100.4F) sustained for >= 1 hour
• Neutropenia: Absolute Neutrophil Count (ANC) < 500 cells/mcL OR < 1000 cells/mcL with expected decline to < 500

This patient has ANC of 200 and fever of 38.9C = Medical Emergency

Pathophysiology of Chemotherapy-Induced Neutropenia

Mechanism:

• Chemotherapy is cytotoxic to rapidly dividing cells
• Bone marrow hematopoietic stem cells are highly proliferative
• Neutrophil precursors are damaged, reducing production
• Nadir (lowest point) typically occurs 7-14 days after chemotherapy
• Duration depends on regimen; recovery usually within 1-2 weeks

Why Neutropenic Fever is Dangerous:

• Neutrophils are primary defense against bacterial and fungal infections
• Without neutrophils, minor infections become life-threatening
• Typical inflammatory signs (pus, infiltrates) may be ABSENT
• Bacteria can rapidly disseminate (sepsis, shock)

Treatment

FEBRILE NEUTROPENIA MANAGEMENT:

1. Immediate Empiric Antibiotics (within 1 hour of presentation):

• Antipseudomonal beta-lactam monotherapy:
• Cefepime 2 g IV every 8 hours, OR
• Piperacillin-tazobactam 4.5 g IV every 6 hours, OR
• Meropenem 1 g IV every 8 hours (if penicillin allergy or ESBL concern)

Why Antipseudomonal Coverage?

• Pseudomonas aeruginosa causes rapid, lethal infections in neutropenic patients
• Must cover gram-negative organisms including Pseudomonas from the start
• Can narrow later based on culture results

2. Additional Coverage Considerations:

• Add vancomycin if:
• Port site infection suspected
• Skin/soft tissue infection
• Hemodynamic instability
• Known MRSA colonization
• Mucositis (oral flora including Streptococcus viridans)
• This patient has mild mucositis - add vancomycin 1 g IV every 12 hours

3. Continue Monitoring:

• Serial vital signs
• Daily CBC to follow ANC recovery
• Repeat blood cultures if persistent fever

4. G-CSF Consideration:

• She already received pegfilgrastim after chemotherapy
• Additional G-CSF generally not indicated for treatment of established febrile neutropenia
• Role is in PRIMARY PREVENTION, not treatment

Understanding Antiemetic Pharmacology

Why Did She Have Breakthrough Nausea?

AC chemotherapy is highly emetogenic (>90% risk without prophylaxis)

Three Phases of Chemotherapy-Induced Nausea:

Optimal Triple Antiemetic Regimen for Highly Emetogenic Chemo:

1. 5-HT3 antagonist: Ondansetron 8 mg or palonosetron 0.25 mg
2. NK-1 antagonist: Aprepitant 125/80/80 mg or fosaprepitant IV
3. Dexamethasone: 12 mg day 1, then 8 mg days 2-4
4. Consider adding: Olanzapine 5-10 mg days 1-4

This patient's regimen was appropriate but may benefit from:

• Olanzapine addition for breakthrough nausea
• Extended dexamethasone (4 days instead of 3)
• PRN lorazepam for anticipatory nausea

Understanding G-CSF (Filgrastim/Pegfilgrastim)

Mechanism:

• Granulocyte Colony-Stimulating Factor (G-CSF)
• Binds G-CSF receptor on myeloid precursors
• Stimulates neutrophil production and maturation
• Accelerates neutrophil release from bone marrow
• Enhances neutrophil function

Indications for Primary Prophylaxis:

• Regimens with >= 20% risk of febrile neutropenia
• Dose-dense regimens (like this patient's)
• Patient factors increasing risk (age > 65, comorbidities)

Timing:

• Filgrastim: Start 24-72 hours after chemo, continue until ANC recovery
• Pegfilgrastim: Single dose 24-72 hours after chemo (long-acting)

She received pegfilgrastim but still developed neutropenia because:

• Even with G-CSF support, nadir neutropenia still occurs
• G-CSF reduces depth and duration of nadir but doesn't prevent it entirely
• Her ANC at day 10 represents the nadir period

Hospital Course

• Blood cultures returned positive for coagulase-negative Staphylococcus (likely port-related)
• Continued vancomycin; cefepime narrowed after cultures finalized
• ANC recovered to 1,500 by hospital day 4
• Discharged to complete oral antibiotics

Follow-up Recommendations

For Future Chemotherapy Cycles:

1. Continue pegfilgrastim (already on)
2. Enhanced antiemetic regimen: Add olanzapine 10 mg days 1-4
3. Education on fever precautions: Check temperature if feeling unwell; come to ED immediately if >= 38.0C
4. Dose modification may be considered if recurrent severe neutropenia

Clinical Pearl

Febrile neutropenia is an oncologic emergency requiring empiric broad-spectrum antibiotics within 1 hour of presentation. The most important coverage is against gram-negative bacteria including Pseudomonas. Even patients receiving G-CSF prophylaxis can develop neutropenia. Chemotherapy-induced nausea involves multiple pathways - highly emetogenic regimens require triple antiemetic therapy targeting serotonin (5-HT3 antagonist), substance P (NK-1 antagonist), and inflammation (dexamethasone). Adding olanzapine improves control of delayed nausea. Prevention of febrile neutropenia with G-CSF and prevention of nausea with appropriate antiemetics are critical for maintaining chemotherapy dose intensity and patient quality of life.

Clinical Image

Image depicting chemotherapy administration through an implanted port. Proper antiemetic prophylaxis and G-CSF support are essential components of chemotherapy management to prevent nausea and reduce the risk of febrile neutropenia.

Image Source: Wikimedia Commons - "Chemotherapy infusion" License: CC BY-SA 4.0 URL: https://commons.wikimedia.org/wiki/File:Chemotherapy_infusion.jpg

All cases for this lecture as Markdown